BridgeBio Pharma Inc (BBIO)

27.44 +0.12 (+0.44%) USD  |  NASDAQ  |  Dec 31, 16:00
27.43 -0.01 (-0.04%) Pre-Market: 20:00
More

BridgeBio Pharma SG&A Expense (Quarterly): 68.82M for Sept. 30, 2024

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for BBIO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense Definition

View SG&A Expense Definition
Start Trial

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Pfizer Inc 3.244B
Alnylam Pharmaceuticals Inc 220.99M
Cassava Sciences Inc 12.95M
Regeneron Pharmaceuticals Inc 714.40M
Vertex Pharmaceuticals Inc 371.80M